Literature DB >> 11119533

Inhibition of adhesion of Plasmodium falciparum-infected erythrocytes by structurally defined hyaluronic acid dodecasaccharides.

W Chai1, J G Beeson, H Kogelberg, G V Brown, A M Lawson.   

Abstract

We recently reported that Plasmodium falciparum-infected erythrocytes (IRBCs) can adhere to hyaluronic acid (HA), which appears to be a receptor, in addition to chondroitin sulfate A (CSA), for parasite sequestration in the placenta. Further investigations of the nature and specificity of this interaction indicate that HA oligosaccharide fragments competitively inhibit parasite adhesion to immobilized purified HA in a size-dependent manner, with dodecasaccharides being the minimum size for maximum inhibition. Rigorously purified and structurally defined HA dodecasaccharides, free of contamination by CSA or other glycosaminoglycans, effectively inhibited IRBC adhesion to HA but not CSA, providing compelling evidence of a specific interaction between IRBCs and HA.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11119533      PMCID： PMC97899          DOI： 10.1128/IAI.69.1.420-425.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  31 in total

1.  NMR studies of a tetrasaccharide from hyaluronic acid.

Authors:  P Livant; L Rodén; N R Krishna
Journal:  Carbohydr Res       Date:  1992-12-31       Impact factor: 2.104

2.  Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria.

Authors:  J G Beeson; S J Rogerson; B M Cooke; J C Reeder; W Chai; A M Lawson; M E Molyneux; G V Brown
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

3.  Cytochemical studies of the maternal surface of the syncytiotrophoblast of human early and term placenta.

Authors:  B J Martin; S S Spicer; N M Smythe
Journal:  Anat Rec       Date:  1974-04

4.  Novel hyaluronidase from streptomyces.

Authors:  T Ohya; Y Kaneko
Journal:  Biochim Biophys Acta       Date:  1970-03-18

5.  An analysis of malaria in pregnancy in Africa.

Authors:  B J Brabin
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

6.  NMR studies of oligosaccharides derived from hyaluronate: complete assignment of 1H and 13C NMR spectra of aqueous di- and tetra-saccharides, and comparison of chemical shifts for oligosaccharides of increasing degree of polymerisation.

Authors:  R Toffanin; B J Kvam; A Flaibani; M Atzori; F Biviano; S Paoletti
Journal:  Carbohydr Res       Date:  1993-07-05       Impact factor: 2.104

7.  Synchronization of Plasmodium falciparum erythrocytic stages in culture.

Authors:  C Lambros; J P Vanderberg
Journal:  J Parasitol       Date:  1979-06       Impact factor: 1.276

8.  Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor.

Authors:  A Walker; J E Turnbull; J T Gallagher
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

9.  Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight.

Authors:  I A McGregor; M E Wilson; W Z Billewicz
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

10.  Immunohistological and biochemical evidence for a role for hyaluronic acid in the growth and development of the placenta.

Authors:  C A Sunderland; J N Bulmer; M Luscombe; C W Redman; G M Stirrat
Journal:  J Reprod Immunol       Date:  1985-11       Impact factor: 4.054
View more
  8 in total

1.  Chondroitin sulfate proteoglycan but not hyaluronic acid is the receptor for the adherence of Plasmodium falciparum-infected erythrocytes in human placenta, and infected red blood cell adherence up-regulates the receptor expression.

Authors:  Arivalagan Muthusamy; Rajeshwara N Achur; Manojkumar Valiyaveettil; John J Botti; Diane W Taylor; Rose F Leke; D Channe Gowda
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

2.  Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies.

Authors:  James G Beeson; Emily J Mann; Timothy J Byrne; Aphrodite Caragounis; Salenna R Elliott; Graham V Brown; Stephen J Rogerson
Journal:  J Infect Dis       Date:  2006-01-30       Impact factor: 5.226

3.  Inhibition of chondroitin-4-sulfate-specific adhesion of Plasmodium falciparum-infected erythrocytes by sulfated polysaccharides.

Authors:  Katherine T Andrews; Nicole Klatt; Yvonne Adams; Petra Mischnick; Reinhard Schwartz-Albiez
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

4.  Heparin increases the infectivity of Human Papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure.

Authors:  Carla Cerqueira; Yan Liu; Lena Kühling; Wengang Chai; Wali Hafezi; Toin H van Kuppevelt; Joachim E Kühn; Ten Feizi; Mario Schelhaas
Journal:  Cell Microbiol       Date:  2013-05-06       Impact factor: 3.715

5.  Structural basis for multiple sugar recognition of Jacalin-related human ZG16p lectin.

Authors:  Mayumi Kanagawa; Yan Liu; Shinya Hanashima; Akemi Ikeda; Wengang Chai; Yukiko Nakano; Kyoko Kojima-Aikawa; Ten Feizi; Yoshiki Yamaguchi
Journal:  J Biol Chem       Date:  2014-04-30       Impact factor: 5.157

6.  Molecular aspects of Plasmodium falciparum Infection during pregnancy.

Authors:  Nicaise Tuikue Ndam; Philippe Deloron
Journal:  J Biomed Biotechnol       Date:  2007

7.  Disruption of var2csa gene impairs placental malaria associated adhesion phenotype.

Authors:  Nicola K Viebig; Emily Levin; Sébastien Dechavanne; Stephen J Rogerson; Jürg Gysin; Joseph D Smith; Artur Scherf; Benoit Gamain
Journal:  PLoS One       Date:  2007-09-19       Impact factor: 3.240

8.  Antibodies from malaria-exposed pregnant women recognize trypsin resistant epitopes on the surface of Plasmodium falciparum-infected erythrocytes selected for adhesion to chondroitin sulphate A.

Authors:  Lisa Sharling; Anders Enevold; Kordai M P Sowa; Trine Staalsoe; David E Arnot
Journal:  Malar J       Date:  2004-09-06       Impact factor: 2.979
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.